Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jun 4, 2026 (4 months ago)

prednisoLONE Acetate Ophthalmic Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

prednisoLONE Acetate Ophthalmic Suspension, USP, 1%, Rx only, Sterile, a) 5 mL (NDC 70748-332-02); b) 10 mL (NDC 70748-332-03), c) 15 mL (70748-332-04), Manufactured by: Lupin Limited, Pithampur (M.P) 454 775, INDIA

Affected NDCs 70748-0332-02 70748-0332-03 70748-0332-04

Compare with the code on your package — it is the most precise check available.

Drug: Prednisolone Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Prednisolone Acetate
NDC 70748-0332
10 mg/mL Suspension/ Drops
Ophthalmic
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
70748-332-02
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0655-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Prednisolone recalls

See all

Other recalls by Lupin Pharmaceuticals Inc.

All 2026 recalls
Class II · Moderate risk

Ganirelix Acetate Injection

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Ongoing Impurity / degradation Lupin Pharmaceuticals Inc. NDC 70748-274-01 D-0220-2026